Rethinking First-Line Therapy and Beyond: HER2-Positive and Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer-Commentary Based on a Live Symposium Presented at the 2025 ESMO Congress in Berlin, Germany
{{output}}
Recent advances in metastatic breast cancer have fundamentally altered treatment paradigms, offering new hope for patients while challenging clinicians to adapt their approaches to patient care. This article summarizes expert perspectives from a symposium pres... ...
